SABCS and ASH findings: palbociclib improves PFS in HR+, HER2+ breast cancer, cilta-cel achieves 100% CR in smoldering MM, and selinexor with ruxolitinib aids myelofibrosis.

Sanjay K. Juneja, MD, discusses how artificial intelligence has evolved in 2024 to help improve early detection of cancer. Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins ...

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase ...

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic ...

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; ...

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple ...

In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the ...

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...